Standard Medication Therapy

Phase 3Small molecule

QQing Yuan

Standard Medication Therapy is one of 96 small molecule programs targeting Kidney Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Overactive BladderActive, not recruiting

Kidney DiseasePreclinical

Active, not recruiting

Intracerebral HemorrhagePhase 3

Active, not recruiting

Overactive BladderPhase 3

Active, not recruiting

Competition

Competitive Landscape

245 competitors in Kidney Disease

#DrugCompanyPhaseTrials

Evrenzo

Astellas

Phase 3

1 2

Zemplar

AbbVie

Phase 3

1 3

Reata

Biogen

Phase 3

1 4

Victoza

Novo Nordisk

Phase 3

1 5

Invirase

Roche

Phase 3

1 6

Edarbi

Takeda

Phase 3

1 7

Myfortic

Aranesp

Gazyva

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Remote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage

Unknown status·—·Phase 3·NCT04657133·452 enrolled

Kidney Disease1 trial

Remote Ischemic Conditioning for the Treatment of Diabetic Kidney Disease

Not yet recruiting·—·N/A·NCT06654921·60 enrolled

Overactive Bladder1 trial

Tibial Nerve Stimulation for Post-BPH Overactive Bladder

Not yet recruiting·QQing Yuan·Phase 3·NCT06558539·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Standard Medication Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Medication Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Medication Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qing Yuan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: QQing Yuan

Standard Medication Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Kidney Disease1 trial

Overactive Bladder1 trial

References

Drug Info

Quick Facts

Related News